102
Participants
Start Date
January 31, 2017
Primary Completion Date
January 27, 2022
Study Completion Date
January 27, 2022
GlucoCorticoid
"After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone."
Hospital Pierre-Paul Riquet, Toujouse
Bordeaux University Hospital, Bordeaux
Brest University Hospital, Brest
Jean Rougier Hospital, Cahors
Clermont-Ferrand Hospital, Clermont-Ferrand
Bicêtre Hospital, Le Kremlin-Bicêtre
Lille Hospital, Lille
Limoges Hospital, Limoges
Montpellier Hospital, Montpellier
Pasteur Hospital, Nice
Orléans Hospital, Orléans
Bichat Hospital, Paris
Cochin Hospital, Paris
La Pitié-Salpétrière, Paris
Lyon Sud Hopsital, Pierre-Bénite
Saint-Etienne Hospital, Saint-Etienne
Strasbourg Hospital, Strasbourg
University Hospital, Toulouse
OTHER